Valence-Engineered Catalysis-Selectivity Regulation of Molybdenum Oxide Nanozyme for Acute Kidney Injury Therapy and Post-Cure Assessment

The study investigates the use of valence-engineered molybdenum oxide nanozymes for treating acute kidney injury (AKI) by modulating their enzyme-like catalytic selectivity. By adjusting the valence states of molybdenum, researchers achieved specific catalase (CAT)-like or peroxidase (POD)-like activities, crucial for reactive oxygen species (ROS)-related therapies. MF-0 nanozymes showed optimal CAT-like activity, while MF-10 exhibited superior POD-like activity. The nanozymes demonstrated promising therapeutic outcomes in vitro and in vivo, improving cell viability and reducing oxidative stress in AKI-induced mice. Additionally, photoacoustic imaging (PAI) was used for non-invasive monitoring of ROS levels, suggesting that these nanozymes could be effective therapeutic and diagnostic tools for AKI and other ROS-related diseases.